Edition:
United States

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

10.38USD
20 Jul 2018
Change (% chg)

$-0.53 (-4.86%)
Prev Close
$10.91
Open
$10.90
Day's High
$10.95
Day's Low
$10.02
Volume
146,599
Avg. Vol
121,719
52-wk High
$37.00
52-wk Low
$3.13

Chart for

About

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $130.21
Shares Outstanding(Mil.): 11.94
Dividend: --
Yield (%): --

Financials

  CBIO.OQ Industry Sector
P/E (TTM): -- 29.12 33.34
EPS (TTM): -5.70 -- --
ROI: -28.65 13.60 13.18
ROE: -33.72 15.30 15.09

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 03 2018

BRIEF-Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset

* CATALYST BIOSCIENCES RECEIVES $1.5 MILLION IN TWO MILESTONE PAYMENTS FOR NEURONAL NICOTINIC RECEPTOR (NNR) ASSET Source text for Eikon: Further company coverage:

Mar 26 2018

BRIEF-Catalyst Biosciences Provides Corporate Update

* CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 01 2018

BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D

* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D

Feb 26 2018

BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Feb 13 2018

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 12 2018

BRIEF-RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences

* RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 Source text: (http://bit.ly/2nDJSqt) Further company coverage:

Feb 05 2018

BRIEF-Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln

* CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text - http://bit.ly/2F2CQC6 Further company coverage:

Jan 22 2018

Competitors

Earnings vs. Estimates